Acadia Pharmaceuticals Inc. (ACAD) Q3 2007 Earnings Results

ACADIA PHARMACEUTICA Misses on EPS — Stock Down 1.51%

The earnings report indicates that ACADIA PHARMACEUTICA is still struggling with its financial performance, as evidenced by the EPS miss. The stock reacted negatively, dropping 1.51% in response to the disappointing results. Investors may be concerned about the lack of revenue data and guidance, which adds uncertainty to the company's future outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.43	N/A	-11.69%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about current financial performance, particularly in relation to EPS. They reiterated their commitment to long-term goals.

Management highlighted ongoing challenges in achieving profitability.

They emphasized a focus on long-term strategy despite short-term setbacks.

ACADIA PHARMACEUTICA Misses on EPS — Stock Down 1.51%

Key numbers

Management commentary

Acadia Pharmaceuticals Inc.

More earnings this week

ACADIA PHARMACEUTICA Misses on EPS — Stock Down 1.51%

Key numbers

Management commentary